Loading company…
Xenikos B.V. develops T-Guard, an immunotherapy for T-cell mediated diseases including steroid-refractory acute GVHD.
Founded in 2009 and based in Nijmegen, Netherlands, Xenikos B.V. develops T-Guard, a combination of two toxin-loaded anti-T-cell antibodies aimed at resetting the immune system in conditions such as grade III/IV steroid-refractory acute graft-versus-host disease. CEO and founder Ypke van Oosterhout leads the company. Its latest round was EUR 40.00 mn of venture debt led by Veloxis Pharmaceuticals A/S on December 19, 2022, and it reports EUR 30.00 mn raised across five deals to date.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in